MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ ​ ​ MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update ​ Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD ​ Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Le

Event · Earnings
Original reporting
Published Nov 13, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MTVA
Bullish
high confidence
Mentioned
$MTVA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MTVABullishMed
01

Why it matters

The disclosed Phase 1 interim results provide the first quantitative efficacy readout, likely prompting short‑term buying interest.

02

Market read

Primary disclosure of quarterly financials and pivotal trial data for a Nasdaq‑listed biotech, offering fresh trading catalysts.

03

What to watch

Rising R&D expenses may pressure cash runway; upcoming financing needs could offset clinical upside.

Relevance 7/10Novelty 8/10Timing: today

Background

MetaVia is a clinical‑stage biotech focused on liver‑related cardiometabolic diseases, trading on Nasdaq under MTVA.

Company-level read

Ticker impact

$MTVABullishHigh confidence
Context

MetaVia filed an 8‑K reporting Q3 2026 results and positive Phase 1 interim data for DA‑1726, a novel OXM analog.

Expected impact

likely upward pressure as investors price in the 68.1% liver‑fat reduction and plan for a Phase 2 study.

Evidence & confidence

First‑report of material clinical data from a listed biotech; trial results historically move share price.

Market effects

Strengthens the liver‑focused metabolic therapy segment and may boost peer biotech sentiment.

Limited to US biotech investors; no broader regional effect.

Modest; impacts global biotech investors tracking metabolic disease pipelines.

Counterpoint

If Phase 2 fails to meet expectations, the current hype could reverse sharply.

Key entities

  • Hyung Heon Kim

    President and CEO of MetaVia, quoted on trial results.

  • Sarah Browne, M.D.

    Newly appointed Chief Medical Officer.

Related articles

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 ​ Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks ​ Positive Part 3B I

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 ​ Statistically Significant Increase in Liver and Circulating FGF21 Expression ​ Greater Glucose Lowering and Comparable Weig